I work in the drug development industry, its a shame this has been downvoted, it's largely true - at least for new drug innovation. The fact that routine procedures are expensive in the US is unrelated.
The US is ~35% of the global pharmaceutical industry, which is the topline driver of new drug development.
When the US pays top dollar for new drugs, it does effectively subsidize European access to the new research.
The US is ~35% of the global pharmaceutical industry, which is the topline driver of new drug development.
When the US pays top dollar for new drugs, it does effectively subsidize European access to the new research.
>Do you have any data to backup your claim?
I would suggest https://www.rand.org/pubs/research_briefs/RB9412.html
or the Great American Drug Deal, by Peter Kolchinsky.